

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/323117121>

# Promising Anti-Hepatitis C Virus Compounds from Natural Resources

Article · May 2016

CITATIONS

0

READS

24

3 authors, including:



Tutik Sri Wahyuni

Airlangga University

1 PUBLICATION 0 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:




HCV drug developments [View project](#)

All content following this page was uploaded by [Tutik Sri Wahyuni](#) on 11 February 2018.

The user has requested enhancement of the downloaded file.

# NATURAL PRODUCT COMMUNICATIONS

An International Journal for Communications and Reviews Covering all  
Aspects of Natural Products Research



**This Issue is Dedicated to  
Professor Dr DHC Yoshinori Asakawa  
On the Occasion of his 75th Birthday**

Volume 11, Issue 8, Pages 1057-1206, 2016  
ISSN 1934-578X (printed); ISSN 1555-9475 (online)  
[www.naturalproduct.us](http://www.naturalproduct.us)



## EDITOR-IN-CHIEF

**DR. PAWAN K AGRAWAL**

Natural Product Inc.  
7963, Anderson Park Lane,  
Westerville, Ohio 43081, USA  
agrawal@naturalproduct.us

## EDITORS

**PROFESSOR ALEJANDRO F. BARRERO**

Department of Organic Chemistry, University of Granada,  
Campus de Fuente Nueva, s/n, 18071, Granada, Spain  
afbarre@ugr.es

**PROFESSOR MAURIZIO BRUNO**

Department STEBICEF,  
University of Palermo, Viale delle Scienze,  
Parco d'Orleans II - 90128 Palermo, Italy  
maurizio.bruno@unipa.it

**PROFESSOR DE-AN GUO**

National Engineering Laboratory for TCM Standardization Technology,  
Shanghai Institute of Materia Medica, Chinese Academy of Sciences,  
Shanghai 201203, P. R. China  
gda5958@163.com

**PROFESSOR VLADIMIR I. KALININ**

G.B. Elyakov Pacific Institute of Bioorganic Chemistry,  
Far Eastern Branch, Russian Academy of Sciences,  
Pr. 100-letiya Vladivostoka 159, 690022,  
Vladivostok, Russian Federation  
kalininv@piboc.dvo.ru

**PROFESSOR YOSHIHIRO MIMAKI**

School of Pharmacy,  
Tokyo University of Pharmacy and Life Sciences,  
Horinouchi 1432-1, Hachioji, Tokyo 192-0392, Japan  
mimaki@ps.toyaku.ac.jp

**PROFESSOR STEPHEN G. PYNE**

Department of Chemistry, University of Wollongong,  
Wollongong, New South Wales, 2522, Australia  
spyne@uow.edu.au

**PROFESSOR MANFRED G. REINECKE**

Department of Chemistry, Texas Christian University,  
Forts Worth, TX 76129, USA  
m.reinecke@tcu.edu

**PROFESSOR WILLIAM N. SETZER**

Department of Chemistry, The University of Alabama in Huntsville,  
Huntsville, AL 35809, USA  
wsetzer@chemistry.uah.edu

**PROFESSOR YASUHIRO TEZUKA**

Faculty of Pharmaceutical Sciences, Hokuriku University,  
Ho-3 Kanagawa-machi, Kanazawa 920-1181, Japan  
y-tezuka@hokuriku-u.ac.jp

**PROFESSOR DAVID E. THURSTON**

Institute of Pharmaceutical Science  
Faculty of Life Sciences & Medicine  
King's College London, Britannia House  
7 Trinity Street, London SE1 1DB, UK  
david.thurston@kcl.ac.uk

## HONORARY EDITOR

**PROFESSOR GERALD BLUNDEN**

The School of Pharmacy & Biomedical Sciences,  
University of Portsmouth,  
Portsmouth, PO1 2DT U.K.  
axuf64@dsl.pipex.com

## ADVISORY BOARD

Prof. Viqar Uddin Ahmad  
Karachi, Pakistan

Prof. Giovanni Appendino  
Novara, Italy

Prof. Yoshinori Asakawa  
Tokushima, Japan

Prof. Roberto G. S. Berlinck  
São Carlos, Brazil

Prof. Anna R. Bilia  
Florence, Italy

Prof. Josep Coll  
Barcelona, Spain

Prof. Geoffrey Cordell  
Chicago, IL, USA

Prof. Fatih Demirci  
Eskişehir, Turkey

Prof. Francesco Epifano  
Chieti Scalo, Italy

Prof. Ana Cristina Figueiredo  
Lisbon, Portugal

Prof. Cristina Gracia-Viguera  
Murcia, Spain

Dr. Christopher Gray  
Saint John, NB, Canada

Prof. Dominique Guillaume  
Reims, France

Prof. Duvvuru Gunasekar  
Tirupati, India

Prof. Hisahiro Hagiwara  
Niigata, Japan

Prof. Judith Hohmann  
Szeged, Hungary

Prof. Tsukasa Iwashina  
Tsukuba, Japan

Prof. Leopold Jirovetz  
Vienna, Austria

Prof. Phan Van Kiem  
Hanoi, Vietnam

Prof. Niel A. Koorbanally  
Durban, South Africa

Prof. Chiaki Kuroda  
Tokyo, Japan

Prof. Hartmut Laatsch  
Göttingen, Germany

Prof. Marie Lacaillle-Dubois  
Dijon, France

Prof. Shoen-Sheng Lee  
Taipei, Taiwan

Prof. Imre Mathe  
Szeged, Hungary

Prof. M. Soledade C. Pedras  
Saskatoon, Canada

Prof. Luc Pieters  
Antwerp, Belgium

Prof. Peter Proksch  
Düsseldorf, Germany

Prof. Phila Raharivelomanana  
Tahiti, French Polynesia

Prof. Luca Rastrelli  
Fisciano, Italy

Prof. Stefano Serra  
Milano, Italy

Dr. Bikram Singh  
Palampur, India

Prof. John L. Sorenson  
Manitoba, Canada

Prof. Johannes van Staden  
Scottsville, South Africa

Prof. Valentin Stonik  
Vladivostok, Russia

Prof. Ping-Jyun Sung  
Pingtung, Taiwan

Prof. Winston F. Tinto  
Barbados, West Indies

Prof. Sylvia Urban  
Melbourne, Australia

Prof. Karen Valant-Vetschera  
Vienna, Austria

## INFORMATION FOR AUTHORS

Full details of how to submit a manuscript for publication in Natural Product Communications are given in Information for Authors on our Web site <http://www.naturalproduct.us>.

Authors may reproduce/republish portions of their published contribution without seeking permission from NPC, provided that any such republication is accompanied by an acknowledgment (original citation)-Reproduced by permission of Natural Product Communications. Any unauthorized reproduction, transmission or storage may result in either civil or criminal liability.

The publication of each of the articles contained herein is protected by copyright. Except as allowed under national "fair use" laws, copying is not permitted by any means or for any purpose, such as for distribution to any third party (whether by sale, loan, gift, or otherwise); as agent (express or implied) of any third party; for purposes of advertising or promotion; or to create collective or derivative works. Such permission requests, or other inquiries, should be addressed to the Natural Product Inc. (NPI). A photocopy license is available from the NPI for institutional subscribers that need to make multiple copies of single articles for internal study or research purposes.

**To Subscribe:** Natural Product Communications is a journal published monthly. 2016 subscription price: US\$2,595 (Print, ISSN# 1934-578X); US\$2,595 (Web edition, ISSN# 1555-9475); US\$2,995 (Print + single site online); US\$595 (Personal online). Orders should be addressed to Subscription Department, Natural Product Communications, Natural Product Inc., 7963 Anderson Park Lane, Westerville, Ohio 43081, USA. Subscriptions are renewed on an annual basis. Claims for nonreceipt of issues will be honored if made within three months of publication of the issue. All issues are dispatched by airmail throughout the world, excluding the USA and Canada.



## Promising Anti-Hepatitis C Virus Compounds from Natural Resources

Tutik Sri Wahyuni<sup>a, b\*</sup>, Chie Aoki Utsubo<sup>c</sup> and Hak Hotta<sup>a, d\*</sup><sup>a</sup>Division of Microbiology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan<sup>b</sup>Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Airlangga University, Jl. Dharmawangsa Dalam, Surabaya 60286, Indonesia<sup>c</sup>Department of International Health, Kobe University Graduate School of Health Sciences, 7-10-2, Tomogaoka, Suma-ku, Kobe 654-0142, Japan<sup>d</sup>Department of Oral Vaccine and Drug Development, Kobe University Graduate School of Health Sciences, 1-5-6 Minatogima-minamimachi, Chou-ku, Kobe 650-0047, Japan

hotta@kobe-u.ac.jp; wahyu\_yuni05@yahoo.com

Received: April 2<sup>nd</sup>, 2016; Accepted: May 19<sup>th</sup>, 2016

Hepatitis C virus (HCV) infection is a major worldwide problem, which involves approximately 170 million people. High morbidity of patients is caused by chronic infection, which leads to liver cirrhosis, hepatocellular carcinoma and other HCV-related diseases. The sustained virological response (SVR) has been markedly improved to be >90% by the current standard interferon (IFN)-free treatment regimens with a combination of direct-acting antiviral agents (DAAs) targeting the viral NS3 protease, NS5A multi-function protein and NS5B RNA-dependent RNA polymerase, compared with 50–70% of SVR rates achieved by the previous standard IFN-based treatment regimens with or without an NS3 protease inhibitor. However, the emergence of DAA-resistant HCV strains and the limited access to the DAAs due to their high cost could be major concerns. Also, the long-term prognosis of patients treated with DAAs, such as the possible development of hepatocellular carcinoma, still needs to be further evaluated. Natural resources are considered to be good candidates to develop anti-HCV agents. Here, we summarize anti-HCV compounds obtained from natural resources, including medicinal plant extracts, their isolated compounds and some of their derivatives that possess high antiviral potency against HCV.

**Keywords:** Hepatitis C virus, Medicinal plants, Extracts, Isolated compounds.

Hepatitis C virus (HCV) is a major cause of liver diseases. Persistent HCV infection will progress to chronic liver diseases including cirrhosis and hepatocellular carcinoma. It has been reported that HCV infects 170 million people in the world [1, 2]. More than 120-130 million people are at risk to develop cirrhosis and/or hepatocellular carcinoma, and importantly, around 350,000 patients die from HCV-related diseases every year. It is estimated that about four million people are chronically infected with HCV in the United States, 5-10 million in Europe, 12 million in India and 1.2 million in Japan. Approximately 80% of the acute cases progress to chronic infection and 20% of them progress to cirrhosis [3]. The HCV genome exhibits a sequence of heterogeneity, based on which HCV is currently classified into seven genotypes (1 to 7) with more than 70 subtypes (1a, 1b, 2a, 2b, etc.) [4]. The prevalence of each genotype varies with different geographic areas. The distribution of HCV genotypes 1, 2, and 3 are widely spread among global areas including the United States, South America, Europe, Australia and Eastern Asia. Genotype 4 is primarily found in Egypt, the Middle East, and Central Africa and genotype 5 in Southern Africa. Genotype 6 is mostly found in Southeast Asia [5, 6]. The distribution of HCV genotypes has an important clinical implication that influences the efficacy of therapies. HCV genotype 1 is most common, representing 46% of all HCV infections, with 22% being subtype 1b. Genotype 3 represents about 22% of all HCV infections, with genotypes 2 and 4 being 13% each, whereas genotypes 6 and 5 represent 2% and 1%, respectively [5].

A triple combination therapy with interferon (IFN)- $\alpha$ , ribavirin and the first generation of HCV NS3 protease inhibitors (telaprevir or boceprevir) has been used since 2011, which provides a higher sustained virological response (SVR) rate of ca. 70% for patients

infected with HCV genotype 1 compared with ~50% achieved by a double combination therapy with IFN- $\alpha$  and ribavirin. More recently, novel direct-acting antiviral agents (DAAs) have been developed and IFN-free oral treatment regimens using a combination of the DAAs have become the standard for HCV treatment, with SVR rates being >90%. Those DAAs include NS5A inhibitors such as daclatasvir and ledipasvir, and NS5B RNA-dependent RNA polymerase (RdRp) inhibitors such as sofosbuvir, in addition to the second generation of NS3 protease inhibitors such as simeprevir, asunaprevir and vaniprevir. The IFN-free oral DAAs regimens are applicable to almost all HCV genotypes and have improved the SVR rate, with reduction in treatment duration and side effects. However, the long-term prognosis of patients treated with DAAs, such as the possible development of hepatocellular carcinoma, still needs to be further evaluated. Moreover, the high cost of the new DAA regimens is also an important issue; not all patients can have access to the therapy, particularly in countries with limited resources [1, 7-10]. Therefore, it would be necessary to find new compounds that not only have good efficacy for all HCV genotypes and drug-resistant strains but also which are available at much lower cost. Several compounds from natural resources and their derivatives have been reported to possess anti-HCV activities that have promise for development into anti-HCV agents. Here, we summarize medicinal plant extracts, isolated compounds and their derivative components that possess anti-HCV activities with diverse mechanisms.

HCV is a member of the genus *Hepacivirus* that belongs to the *Flaviviridae* family. The HCV genome consists of positive-sense single-stranded RNA of 9.6 kb with highly structured 5'- and 3'-untranslated regions (UTRs) (Figure 1). The viral genome encodes a polyprotein of about 3,000 amino acid residues, which is cleaved by






Figure 1: HCV genome organization.

The HCV genome contains a single open reading frame (ORF) of RNA that is flanked with 5'- and 3'-untranslated regions (UTRs). The 5'-UTR contains an internal ribosome entry site (IRES). The IRES-mediated translation of ORF generates a polyprotein, which is cleaved into ten viral proteins, structural proteins (Core, E1 and E2) and nonstructural proteins (NS2, NS3, NS3/4A, NS4B, NS5A and NS5B). Red arrows, cleavage by signal peptidase and the signal peptide peptidase; orange arrow, autocatalytic cleavage by NS2-NS3 metalloprotease; blue arrows, cleavage by NS3-NS4A serine protease. The functions of the individual protein are explained in the text.

the host and viral proteases to generate structural proteins (core, E1 and E2), a putative ion channel (p7), and nonstructural proteins (NS2, NS3, NS3/4A, NS4B, NS5A, and NS5B) [11-13]. Each of these proteins has a significant role in HCV entry, replication, and particle formation, and therefore, can be a potential antiviral target(s). The E1 and E2 glycoproteins are involved in HCV entry steps, such as viral attachment and fusion. They are responsible for binding to a number of different virus receptor molecules on the cell surface, such as claudin 1 (CLDN1), scavenger receptor class B type I (SR-B1), CD81 and occludin (OCLN). On the other hand, nonstructural proteins play crucial roles in virus replication. They serve to coordinate the intracellular events of HCV replication, including HCV RNA synthesis, protein synthesis, virus assembly, and modulation of host defense mechanisms. The NS2 metalloprotease mediates cleavage between NS2 and NS3. NS3 exerts a serine protease activity that is responsible for the cleavage at the remaining cleavage sites of the polyprotein. NS3 also possesses a helicase activity that can be regulated by the interaction between the serine protease and helicase domains of NS3, and it is required for replication of the virus. NS4A stabilizes NS3 by forming a complex with it and also acts as an inducer of membrane alterations. NS4B is a hydrophobic protein and is involved in the membranous web formation, a characteristic feature of HCV-infected cells. NS5A is a phosphoprotein that is capable of interacting with the 3'-UTR of the HCV genome and is involved in viral RNA replication and particle assembly. The nonstructural proteins, NS3/4A, NS4B, NS5A and NS5B, form replication complexes that generate *de novo* viral genomic RNA [11, 13-17].

The HCV life cycle can be divided into several steps, i.e., viral attachment/entry, uncoating, viral translation, viral replication, viral assembly and release of the new virion (Figure 2). In the attachment/entry step, the HCV lipoviral particles attach to the cell surface and interact with glycosaminoglycans (GAG), low-density lipoprotein receptor (LDLR), SR-B1 and CD81. Then, the viral interaction with CLDN1 results in internalization of the virus via clathrin-mediated endocytosis. Following acidification of the endosome and subsequent fusion of viral and endosomal membranes, the viral genome is released into the cytoplasm. On the other hand, the lateral movement of HCV-CD81 causes the transmission of virus by cell-to-cell contact [17, 18]. The incoming viral genome is translated through an internal ribosome entry site (IRES) that is located in the 5'-UTR of the viral genome. The 5'- and 3'-UTRs contain highly structured elements that are critical for genome translation, replication and encapsidation. The IRES

initiates translation of the HCV genome into a single polyprotein. Following translation and cleavage of the HCV polyprotein, the nonstructural viral proteins, NS3/4A, NS4B, NS5A and NS5B, form replication complexes, which generate new viral genome RNA molecules. The HCV nonstructural proteins, together with cellular factors, mediate the formation of a membranous web, where the HCV RNA replication takes place. The NS3/4A, NS4B, NS5A, and NS5B are the viral proteins of the replication machinery, which replicates the positive sense RNA genome through the negative strand. The NS5B viral RdRp is the primarily essential enzyme for RNA synthesis. The RNA genome is translated to produce viral proteins, and also serves as the RNA template for further RNA replication. The newly replicated viral genomes are transferred to the assembly sites, where the HCV virion morphogenesis is tightly linked to the metabolism of VLDL assembly. The viral core protein interacts with genomic RNA to form the nucleocapsid, which is then covered in the viral envelope through the viral budding into the endoplasmic reticulum (ER) lumen on the site of VLDL production. After assembly and budding into the ER, HCV particles are released from the cells through the secretory pathway [13, 14, 18, 19].

The HCV proteins, HCV-specific RNA structures as well as host factors, are important targets of anti-HCV drugs. The new generations of DAAs have been developed as anti-HCV drugs for treatment of chronic HCV infection. Telaprevir, boceprevir, simeprevir, faldaprevir, vaniprevir, asunaprevir, paritaprevir, sofosbuvir and grazoprevir are the first and second generations of NS3 protease inhibitors. On the other hand, daclatasvir, ledipasvir, ombitasvir, elbasvir and velpatasvir are known as NS5A inhibitors, and sofosbuvir, beclabuvir and dasabuvir as NS5B RdRp inhibitors [10, 20]. These DAAs have been approved by the United States Food and Drug Administration (FDA) for HCV treatment in combination with pegylated IFN and ribavirin or as IFN-free regimens. The current regimens with IFN-free DAAs have increased the SVR rates and are applicable for almost all patients except for those infected with drug-resistant strains. Sofosbuvir, a nucleotide NS5B RdRp inhibitor, is approved for treatment of patients with HCV genotypes 1, 2, 3 and 4 in combination with other DAAs. Daclatasvir, an NS5A inhibitor, has been approved by FDA for HCV genotypes 1, 3 and 4. Also, a triple combination of NS3, NS5A and NS5B inhibitors (asunaprevir, daclatasvir and beclabuvir, respectively) has been shown to be effective for HCV genotypes 1 through 5 and some strains of genotype 6. Another triple combination of ritonavir-boosted paritaprevir, ombitasvir and dasabuvir was used for HCV genotype 1 [7-10, 15, 16].






Figure 2: HCV life cycle and targets of natural compounds.

HCV infects hepatocytes by an attachment step at the cell surface and interacts with receptors on the host cells; first, interacts with glycosaminoglycans (GAG), associated with low density lipoprotein-receptor (LDL-R) and binds with entry factors, CD81, SRB1, CLDN1, and OCLN. Virus particles enter the cells via clathrin-mediated endocytosis and the low pH of the endosomal compartment induces HCV fusion. The viral genome is released into cytosol and continues for translating and polyprotein processing for RNA replication and towards virus assembly. Virus particles are assembled by recruiting E1 and E2 complexes, followed by budding into the ER, and HCV particles are released from the cells to infect new host cells.

In addition, several compounds that inhibit HCV replication by targeting host factors, such as alisporivir, a cyclophilin inhibitor, and miravirsin, a miR-122 antagonist, have also been reported [15]. Although the IFN-free DAA regimens have dramatically improved the outcome of HCV treatment, not all patients can access to the new therapy due to the high cost.

Developing anti-HCV agents from medicinal plants has currently become a significant issue. Products from medicinal plants are generally cost effective and easily available in many parts of the world. Medicinal plants contain many metabolites, both the secondary metabolites such as flavonoids, alkaloids, coumarins and polyphenol compounds, and primary metabolites such as peptides, which have been reported to possess antiviral effects including anti-HCV activities. We have summarized the medicinal plant extracts (Table 1), isolated compounds (Table 2) and their derivatives (Table 3) that inhibit HCV infection. Table 1 shows medicinal plant extracts that exert anti-HCV activities with  $IC_{50}$  values of less than 50  $\mu\text{g}/\text{mL}$ . Medicinal plant extracts from Indonesia: *Toona sureni*, *Melicope latifolia*, *Melanolepis multiglandulosa*, *Ficus fistula* and *Ruta angustifolia* possess anti-HCV activities with  $IC_{50}$  values of 1.6 -17.1  $\mu\text{g}/\text{mL}$  [21, 22]. *T. sureni* and *M. latifolia* inhibit HCV both at the entry and the post-entry steps, and decrease HCV RNA levels while *M. multiglandulosa* and *F. fistula* show significant HCV inhibition at the entry step. Moreover, these plant extracts

mediated strong inhibition against almost all HCV genotypes [21]. As for the plant extracts derived from Cameroon, methanol extracts of *Trichilia dregeana*, *Detarium microcarpum* and *Phragmanthera capitata* were shown to possess anti-HCV activities by inhibiting the entry step, but showed no inhibition effect on viral replication and virion release [23].

Methanol and water extracts of Sudanese medicinal plants, *Boswellia carterii*, *Acacia nilotica*, *Embelia schimperi*, *Quercus infectoria* and *Syzygium aromaticum*, inhibited HCV protease activity by >90% at the concentration of 100  $\mu\text{g}/\text{mL}$  [31]. Some traditional Chinese medicines, *Ligustrum lucidum* fruit and *Glycyrrhiza uralensis*, were also reported to have anti-HCV activities [24]. The ethyl acetate fractions of *L. lucidum* fruit mediated anti-HCV inhibition by acting on NS5B RdRp and thus blocking HCV RNA replication [25]. *G. uralensis*, commonly known as licorice, has been widely used in Chinese medicine. It contains about 20 triterpenoids and 300 flavonoid compounds. This plant was shown to decrease HCV particle release and possess an additive effect in combination with IFN- $\alpha$  [35, 36]. A methanol extract of *Embelia ribes* and a water extract of *Limonium sinense* root inhibit HCV infection at the entry step while extracts of *Phyllanthus amarus*, *Platycodon grandiflorum*, *Garcinia mangostana* and other medicinal plants inhibited HCV replication [26-30, 32-34]. The antiviral activities of these plant extracts might



Table 1: Plant extracts that possess anti-HCV activities.

Plant name	Plant part	Extract/ Fraction	IC <sub>50</sub>	Viral target/ mechanism	Ref.
<i>Trichilia dregeana</i> (Meliaceae)	root	methanol	16.2 µg/mL	Inhibit HCV entry	[23]
<i>Detarium microcarpum</i> (Caesalpinaceae)	stem	methanol	1.4 µg/mL		
<i>Pragmanthera capitata</i> (Loranthaceae)	leaves	methanol	13.2 µg/mL		
<i>Ruta angustifolia</i> (Rutaceae)	leaves	ethanol, hexane, dichloromethane, and methanol	1.6 – 15.6 µg/mL	Inhibit HCV J6/JFH1	[22]
<i>Glycyrrhiza uralensis</i> (Fabaceae)	roots	methanol	20 µg/mL	Inhibit HCV J6/JFH1	[24]
		chloroform	8.0 µg/mL		
<i>Toona sureni</i> (Meliaceae)	leaves	ethanol	2 – 13.9 µg/mL	Inhibit HCV J6/JFH1 and all HCV genotypes	[21]
<i>Melicope latifolia</i> (Rutaceae)	leaves	ethanol	2.1 – 3.5 µg/mL		
<i>Melanolepis multiglandulosa</i> (Euphorbiaceae)	stem	ethanol	6.2 – 17.1 µg/mL		
<i>Ficus fistula</i> (Moraceae)	leaves	ethanol	5.7 – 15.0 µg/mL		
<i>Ligustrum lucidum</i> (Oleaceae)	fruit	water, ethyl acetate	10 µg/mL	Inhibit HCV NS5B RdRp and HCV replication	[25]
		water	11.9 – 51 µg/mL		
<i>Platycodon grandiflorum</i> (Campanulaceae)	root	water	35 µg/mL	Inhibit RNA replication against Con-1 and JFH1, and decrease NS5B level.	[26]
<i>Embelia ribes</i> (Primulaceae)	root	methanol	-	Inhibit HCV entry	[27]
<i>Phyllanthus amarus</i> (Euphorbiaceae)	root leaves	methanol	5 – 10 µg/mL	Inhibit HCV NS5B	[28]
<i>Garcinia mangostana</i> L. (Clusiaceae)	fruit peels	ethanol	5.5 µg/mL	Inhibit HCV replication, decrease NS5A and ROS levels in HCV	[29]
<i>Pinus massoniana</i> (Pinaceae)	bark	-	9.6 µg/mL	Inhibit HCV replication, inhibit HCV NS3	[30]
<i>Acacia nilotica</i> (Mimocaceae), <i>Boswellia carterii</i> (Burceraceae), <i>Embelia schimperi</i> (Myrsinaceae), <i>Quercus infectoria</i> (Fagaceae), <i>Syzygium aromaticum</i> (Myrtaceae), <i>Piper cubeba</i> (Piperaceae)	-	methanol and water	1 – 40.5 µg/mL	Inhibit HCV protease	[31]
<i>Limonium sinense</i> (Plumbaginaceae)	root	water	9.71 µg/mL	Inhibit viral entry, attachment and fusion. Inactivate cell-free virion	[32]
				Inhibit virus binding to the host cell receptor.	
<i>Morinda citrifolia</i> (Rubiaceae)	leaves	methanol	20.6 µg/mL	Inhibit HCV J6/JFH1	[33]
<i>Dimocarpus longan</i> (Sapindaceae)	leaves		19.4 µg/mL	Inhibit HCV primarily through a direct virucidal effect	[34]

be a sum of additive, synergistic or antagonistic effects of the mixed components of the extracts. The potential plant extracts are promising candidates as the drug of choice for alternative or complementary medicine for the treatment of HCV infection.

Further purification to obtain compounds responsible for anti-HCV activities is needed. Moreover, to increase the anti-HCV potency of the isolated compounds, structure modification to produce the semi-synthetic/derivative compounds has been made. Table 2 shows the isolated compounds from plants that exhibit anti-HCV activities, while Table 3 shows the semi-synthetic compounds. Benzoquinone compounds, embelin and 5-O-methylembelin, isolated from *E. schimperi*, were found to inhibit HCV protease at the concentrations of 21 and 46 µM, respectively [31]. Purification from *Maytenuis ilicifolia* and *Peperomia blanda*, Brazilian plants, yielded an alkaloid component, APS (IC<sub>50</sub> 2.3 µM) and lignan compounds (IC<sub>50</sub> 4.0 – 38.9 µM), that inhibited replication of HCV, including daclatasvir-resistant mutant subgenomic replicon [37]. Chalepin and pseudane IX, a coumarin and an alkaloid, both of which were isolated from *R. angustifolia*, inhibited HCV at the post-entry step and decreased the levels of HCV RNA replication and viral protein synthesis [22]. Interestingly, another alkaloid, caffeine, which is abundantly found in coffee, was shown to inhibit HCV with an IC<sub>50</sub> of 0.72 mM. Caffeine acts by delaying fibrosis, and improving the function of liver cellular pathways, in addition to inhibiting HCV replication [38]. Potent alkaloids isolated from *Myrioneuron faberi*, which possess novel cyclohexane-fused oxtetrahydroquinolizine skeletons, inhibit HCV replication [39].

Terpenoid saponins from *P. grandiflorum*: platycodin D, D2, and D3, deapioplatycodin D, and D2 and platyconic acid A, were identified as active compounds for anti-HCV activities, which are shown to exert directly on NS5B RdRp, but did not show any inhibitory effect on NS3 protease. Animal experiments using a saponin mixture from *P. grandiflorum* revealed its half-life of 6.57 ± 0.7 h in rat and showed higher absorption from the duodenum and ileum than from the oral cavity. This might suggest that the

compound could be absorbed better when used as an enteric-coated product. A clinical study using a coated product demonstrated decreased HCV titers by >2 logs after 8-weeks treatment in chronic HCV patients [26]. Other anti-HCV terpenoids that were isolated from fruits of *L. lucidum* are oleanic acid and ursolic acid. These compounds inhibit HCV replication and NS5B RdRp activity. A combination of oleanic acid and ursolic acid with IFN-γ significantly reduced HCV NS5A protein expression [25]. Andrographolide, a diterpenoid lactone from *Andrographis paniculata*, was identified to inhibit HCV replication by targeting host factors. This compound interferes with HCV replication by activating p38 MAPK phosphorylation, which stimulated nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated heme oxygenase-1 gene expression. A combination of andrographolide with IFN-α, telaprevir or PSI-7977 (NS5B inhibitor) revealed a synergistic effect [40]. On the other hand, flavonoid components also offer a bright part of the anti-HCV agent. Several flavonoids have been identified to inhibit HCV infection. Epigallocatechin-3-gallate (EGCG), which is present in green tea (*Camellia sinensis*), was reported to inhibit the HCV entry step in cell-to-cell transmission [41,66]. The structure-activity relationship demonstrated that the gallate ester hydroxyl groups are not essential for anti-HCV activity. However, the hydroxyl groups from the B-ring of EGCG play an important role in binding to HCV during the attachment/entry step [42]. A recent report described EGCG significantly enhancing HCV dsRNA-induced expression of IFN-λ1, Toll-like receptor 3 (TLR3), a retinoic acid-inducible gene I (RIG-I) and antiviral IFN-stimulated genes (ISGs), the important host factor(s) for intracellular innate immunity in hepatocytes [43]. A clinical trial study of healthy volunteers with an oral dose of 800 mg of EGCG per day over four weeks, which equals 8-16 cups of green tea, showed no toxic effects, however, this dose was not enough to eliminate HCV completely due probably to its poor *in vivo* bioavailability [41, 44]. Another natural compound, delphinidin, which has a similar molecular structure to EGCG, was identified as an anti-HCV entry inhibitor. Delphinidin acts directly on the virus particle and impairs viral attachment to the cell surface. This compound inhibits HCV



entry more efficiently than EGCG at the concentration of 50  $\mu\text{M}$ . The  $\text{IC}_{50}$  value of delphinidin was  $3.7 \pm 0.8 \mu\text{M}$ , while that of EGCG was  $10.6 \pm 2.9 \mu\text{M}$ . Other polyphenol compounds, tricetinidin chloride, cyanidin chloride and myricetin, showed only moderate inhibition against the JFH1 strain of HCV. It was considered that trihydroxyphenyl and hydroxyl moieties in the benzene ring of flavonoids have an important contribution for their anti-HCV activities. The combination between delphinidin (5 and 10  $\mu\text{M}$ ) with IFN- $\alpha$  and boceprevir significantly potentiated the activity of IFN- $\alpha$  and boceprevir. The addition of delphinidin at the concentration of 5  $\mu\text{M}$  potentiated the anti-HCV activity of boceprevir up to 5 fold ( $\text{IC}_{50}$  values from 0.15  $\mu\text{M}$  to 0.03  $\mu\text{M}$ ) and that of IFN- $\alpha$  by 10 fold ( $\text{IC}_{50}$  values from 6.30 IU/mL to 0.59 IU/mL). It was also observed that delphinidin and EGCG altered the morphology of HCV pseudoparticles (HCVpp) due possibly to a direct effect on the surface of HCVpp, including the E1/E2 glycoproteins [45]. Other isolated compounds that were reported to inhibit the entry step are grosheimol and cynaropicrin, isolated from wild Egyptian artichoke, which possess  $\text{IC}_{50}$  values between 0.4 and 4  $\mu\text{M}$ . These compounds act directly on the viral particle and may prevent the virus-receptor interaction [46]. Currently, some of the isolated compounds from medicinal plants with anti-HCV activities are under clinical studies, such as naringenin, which is reported to be in phase 1 clinical study, and silymarin/silibinin, which is in phase 2/3 [18]. Both of them are bioflavonoid compounds that exert inhibition against HCV. Naringenin blocked NS5A-driven IRES-mediated translation of the viral genome [47]. Silymarin is a seed extract of *Silybum marianum*. This extract consists of eight flavonolignans, silybin A (16%), silybin B (24%), isosilybin A (6%), isosilybin B (4%), silydianin (16%), silychristin (12%), isosilychristin (2%), and taxifolin (2%). Monotherapy with oral administration of silymarin mediates little effect on viral enzymes and viral loads. Therefore, silymarin is used as a botanical medicine for complementary or alternative treatment and the impact of oral silymarin in combination with IFN- $\alpha$ , ribavirin or DAAs should be investigated [48, 49]. A randomized clinical trial of silymarin for patients with chronic HCV infection found that oral silymarin administration did not exert any significant effect on alanine amino transferase (ALT) and HCV RNA levels compared with the placebo/control group [50]. The impact of the anti-HCV activities of both silymarin and EGCG was relatively weak compared with the other DAAs in the *in vitro* culture cells [51]. Studies to improve the activity and bioavailability of these compounds are still ongoing. Another study of intravenous administration of silibinin (purified compound of silymarin) during the peri-transplant period evidenced antiviral properties that decreased viral load [52]. Ladanein, quercetin, and apigenin are other flavonoid compounds possessing anti-HCV activities [53]. Apigenin inhibits HCV replication and decreases the expression level of miR-122 [54].

Some polyphenols, such as curcumin, resveratrol, exocarpin D and corilagin, were found to have potential as anti-HCV substances [57,65]. Curcumin is a diarylheptanoid that possesses two phenol moieties. Curcumin was reported to act as an anti-inflammatory by suppressing pro-inflammatory cytokines and chemokines such as tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL)-1 $\beta$ , and CXCL8.

It also activates antioxidant responses by activation of transcription factor, nuclear factor erythroid-derived 2-like 2 (Nrf2), which induces the expression of heme oxygenase 1, glutathione S-transferase (GST), and NAD(P)H-quinone oxidoreductase 1. These effects were modulated by other transcription factors, including NF- $\kappa\text{B}$ ,  $\beta$ -catenin, and signal transducer and activator of transcription 3 (STAT3) [55, 56]. Curcumin inhibits the entry step of all HCV genotypes. However, it has no effect on HCV replication and

assembly. Curcumin influences the fluidity of the HCV envelope and impairs viral binding and fusion. The membrane fluidity is controlled by anisotropic rotation of the phospholipid acyl chain and flip-flop movement of membrane molecules that affects membrane rigidity. Curcumin penetrates into the membrane and changes its rigidity. Curcumin also interferes with cell-to-cell transmission of HCV. Two of the curcumin derivatives, desmethoxycurcumin and bis-desmethoxycurcumin, also exert anti-HCV activity. However, the main metabolite of curcumin, tetrahydrocurcumin, did not show any significant inhibitory effect against HCV, indicating that the different structures on  $\alpha$ - and  $\beta$ -unsaturated ketone groups play an importance role in anti-HCV activities [57]. Curcumin is an attractive antiviral candidate with a safety profile in humans and low cost. Phase 1 clinical study demonstrated no treatment-related toxicity. Animal experiments showed an improved bioavailability of curcumin when administered as nanoparticle and nanocrystal formulations [58]. Other polyphenols that inhibit HCV replication are  $\alpha$ -mangostin and  $\gamma$ -mangostin, isolated compounds from *Garcinia mangostana*. Both of them reduced HCV RNA and NS3/NS5A protein levels. An ethanol extract of mangosteen was shown to decrease the reactive oxygen species (ROS) level in HCV-infected cells, while not inhibiting NS5B RdRp and IRES-dependent translation [29]. Novel derivatives of quercetin, 7-*O*-arylmethylquercetin and quercetin-3-*O*-benzoic acid ester, exhibited anti-HCV activities. Compound 3i, which has a 3-chlorobenzyl substitution in 7-*O*-arylmethylquercetin, showed stronger activity ( $\text{IC}_{50}$ : 3.8  $\mu\text{M}$ ) than that with substitution of carboxyl groups at quercetin-3-*O* ( $\text{IC}_{50}$ : 9.0  $\mu\text{M}$ ). This quercetin analog exerted potent inhibition of HCV NS5B RdRp activity through chelation of magnesium ions at the active site [59]. Other derivatives such as imidazo derivatives were also potent inhibitors of HCV [60, 61]. Compound 5o, an imidazo[1,2-*a*][1,8]naphthyridine derivative, revealed promising pharmacokinetics in rat at the concentration of 100 mg/kg [60]. A safe pharmacokinetic profile was also observed with MK-8831, which showed a bioavailability of 31% in rat and 17% in dog [62, 63]. A series of phenylalanine-based macrocyclic inhibitors, boronate-based inhibitors, phenylglycine-based inhibitors,  $\alpha$ -ketoamide-based inhibitors, sulfonamide-capped inhibitors, indole derivatives, acridone derivatives and oleanolic acid derivatives have been designed as HCV NS3 protease inhibitors. Those NS3 protease inhibitors are considered as peptidomimetics, which mimic cleavage products (peptides) and inhibit the enzyme activity. Also, macrocyclic  $\alpha$ -ketoamides were found to be potent HCV NS3 protease inhibitors [64]. Other semi-synthetic compounds possessing Ant-HCV activities are listed in Table 3.

Clemizole, anguizole and their structurally related compounds, *N*-(4-indol-2-yl)phenyl sulfonamides, 6-(indol-2-yl)pyridine-3-sulfonamides and piperazine derivatives were developed as NS4B inhibitors. These compounds inhibit HCV replication by preventing either NS4B RNA binding activity or membranous web formation [74].

In conclusion, diverse natural resources, including medicinal plant extracts and their isolated compounds, interfere with HCV replication at different steps of the HCV life cycle. Many of the natural resources, especially herbal medicines, have been used for traditional medicine, with relatively less side effects and lower cost. The compounds described in this review article could be promising candidates for anti-HCV drugs. Increasing the antiviral potency by modification of the molecular structures would be an important strategy for developing clinically useful anti-HCV drugs. Also, *in vivo* study is necessary for drug development. Further studies on mechanisms of action, efficacy, pharmacokinetics and safety, both *in vitro* and *in vivo*, are greatly needed.



Table 2: Anti-HCV compounds isolated from medicinal plants.

Compound	Plant name (plant part)	IC <sub>50</sub>	Viral target	Ref.
Embelin	<i>Embelia schimperi</i> (fruit)	21 µM	Inhibit HCV NS3 protease	[31]
5-O-Methyl embelin		46 µM		
Chalepin	<i>Ruta angustifolia</i> (leaves)	1.7 µg/mL	Inhibit HCV replication and decrease the NS3 protein level	[22]
Pseudane IX.		1.4 µg/mL		
Oleanolic acid	<i>Ligustrum lucidum</i> (fruit)	0.8 - 3.5 µg/mL	Inhibit HCV replication, HCV NSSB RdRp	[25]
Ursolic acid		3.1 - 19.2 µg/mL		
APS (alkaloid)	<i>Maytrenus ilicifolia</i> (root bark)	2.3 µM	Inhibit HCV replication and decrease the NSSA level	[37]
Compound 3*43, 3*20 and 5*362	<i>Peperomia blanda</i> (aerial)	4.0, 8.2, 38.9 µM respectively.		
Glycycomarin	<i>Glycyrrhiza uralensis</i> (roots)	4.6 - 8.8 µg/mL	Inhibit post-entry step, Inhibit HCV NS3 protease	[24]
Glycerin, Glycerol				
Excoecariphenols D	<i>Excoecaria agallocha</i> L.	3.4 - 9.0 µM	Inhibit HCV NS3-4A protease and RNA replication	[65]
Corilagin, Geraniin and Chebulagic acid				
Platycodin D, D2, and D3; Deapioplatycodin D, and D2; Platyconic acid A	<i>Platycodon grandiflorum</i> (roots)	0.35 - 2.45 µg/mL	Inhibit RNA replication against Con-1 and JFH1 Inhibit NSSB but not NS3 protease level	[26]
Grosheimol	<i>Cynara cardunculus</i> (leaves)	0.4 - 1.4 µM	Inhibit HCV pan-genotypes	[46]
Cynaropicrin			Inhibits entry step by cell to cell transmission. Directly act on the virus particle and prevent virus-receptor interaction.	
Saikosaponin b2	<i>Bupleurum kooi/ Embelia ribes</i> (roots)	16.1 µM	Inhibit HCV entry, neutralization of virus particle, attachment, and fusion. Bind to E2 and disrupt E2-CD81 interaction.	[27]
β-Myrifabral A	<i>Myrioneuron faberi</i> (aerial)	0.9 - 4.7 µM	Inhibit HCV replication	[39]
α-Myrifabral A				
β-Myrifabral B				
α-Myrifabral B and their derivatives				
α-Mangostin	<i>Garcinia mangostana</i> (fruit peels)	6.3 µM	Inhibit HCV replication and decrease the NS3 and NSSA levels	[29]
γ-Mangostin		2.7 µM		

Table 3: Semi-synthetic compounds and other anti-HCV agents from existing medicines.

Compound (plant origin)	IC <sub>50</sub>	Viral target/ mechanism	Ref.
Glycyrrhizin ( <i>Glycyrrhiza uralensis</i> ; root)	16.5 µM	Inhibit HCV assembly and release by inhibiting phospholipase A2 (PLA2) and HCV NS3 protease	[24, 35, 36]
Andrographolide ( <i>Andrographis paniculata</i> ; aerial)	5.1 - 6 µM	Inhibit HCV replication by up-regulating the heme oxygenase-1 gene via the p38 MAPK/Nrf2 pathway	[40]
EGCG ( <i>Camellia sinensis</i> ; leaves)	5 - 21 µM	Inhibit HCV entry steps (attachment) Interfere with E1/E2 glycoprotein Enhance intracellular innate immunity against HCV	[42, 43, 45, 66]
Delphinidin (anthocyanidin in plant pigment)	3.7 µM	Inhibit HCV in the early step of entry (E1E2 glycoprotein)	[45]
Curcumin, Desmethoxycurcumin, Bis-desmethoxycurcumin ( <i>Curcuma</i> species; rhizome)	8.46 µM	Inhibit HCV entry by affecting membrane fluidity	[55-57]
Apigenin	50 µM	Inhibit cell-to-cell transmission	[54]
Caffeine ( <i>Coffea</i> species)	0.7 mM	Inhibit HCV virus replication by decreasing miR22 expression level	[38]
Licochalcone-A ( <i>Glycyrrhiza</i> species; root and rhizome)	2.5 µg/mL	Inhibit HCV, dominantly acts in the post entry step.	[24, 36]
Glabridin ( <i>Glycyrrhiza</i> species; root and rhizome)	6.3 µg/mL		
Isoliquiritigenin ( <i>Glycyrrhiza</i> species; root and rhizome)	16.4 µg/mL		
5-Carba-pterocarpens derivatives	1.5 - 5.5 µM	Inhibit HCV replicon and decrease HCV NS3 protease	[67]
7-O-Arylmethylquercetin derivate (compound 3i)	3.8 µM	Inhibit HCV RdRp	[59]
Quercetin-3-O-benzoic acid ester derivative (compound 4f)	9.0 µM		
Imidazo [2,1-b]thiazole derivative (compound 26f and 28g)	16 nM and 31 nM, respectively	Inhibit HCV NS4B (inhibit the second amphipathic α-helix of NS4B(4BAH2))	[61]
Imidazo[1,2-α][1,8]naphthyridine (compound RO81991) derivative (compound 5o)	0.017 - 0.159 µM	Inhibit HCV entry step	[60]
2-(4-sulfonamidophenyl)-indole 3 carboxamides	7 nM (GT-1a) and 2 nM (GT-1b)	Inhibit HCV NS4B	[68]
MK-8831	0.004 - 3.4 nM	Inhibit HCV-NS3/4a protease	[63]
MK-4882	0.001 - 0.4 nM	Inhibit HCV genotype 1a, 1b and 2a, potent NSSA inhibitor	[62]
Flunarizine	0.38 µM	Inhibit HCV entry by inhibiting membrane fusion (E1 and/or E2)	[69-71]
Fluphenazine, trifluopenazine and pinozide	0.5 - 1.0 µM	Inhibit entry step (E1 and/or E2)	[69]
Chloroquine ( <i>Cinchona succubra</i> ; bark)	3.93 µM	Inhibit HCV entry by impairing endosome-mediated virus entry	[72, 73]
Ferroquine	0.26 - 0.85 µM	Inhibit all HCV genotype; inhibit entry step/fusion (E1)	[71, 73]

## References

- [1] Lange CM, Jacobson IM, Rice CM, Zeuzem S. (2014) Emerging therapies for the treatment of hepatitis C. *EMBO Molecular Medicine*, 6, 4-15.
- [2] Chan J. (2014) Hepatitis C. *Disease-a-Month*, 60, 201-212.
- [3] Pawlowsky JM. (2013) NSSA inhibitors in the treatment of hepatitis C. *Journal of Hepatology*, 59, 375-382.
- [4] Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J. (2009) Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. *Hepatology*, 49, 364-377.



- [5] Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. *Journal of Hepatology*, **61**, S45-57.
- [6] Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology*, **59**, 318-327.
- [7] Gonzalez-Grande R, Jimenez-Perez M, Gonzalez Arjona C, Mostazo Torres J. (2016) New approaches in the treatment of hepatitis C. *World Journal of Gastroenterology*, **22**, 1421-1432.
- [8] Kiser JJ, Flexner C. (2013) Direct-acting antiviral agents for hepatitis C virus infection. *Annual Review of Pharmacology and Toxicology*, **53**, 427-449.
- [9] Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. (2015) From non-A, non-B hepatitis to hepatitis C virus cure. *Journal of Hepatology*, **62**, S87-S99.
- [10] Tamori A, Enomoto M, Kawada N. (2016) Recent advances in antiviral therapy for chronic hepatitis C. *Mediators of Inflammation*, **2016**, 6841628.
- [11] Rupp D, Bartenschlager R. (2014) Targets for antiviral therapy of hepatitis C. *Seminars in Liver Disease*, **34**, 9-21.
- [12] Moradpour D, Penin F, Rice CM. (2007) Replication of hepatitis C virus. *Nature Reviews Microbiology*, **5**, 453-463.
- [13] Dubuisson J, Cosset FL. (2014) Virology and cell biology of the hepatitis C virus life cycle - an update. *Journal of Hepatology*, **61**, S3-S13.
- [14] Madan V, Bartenschlager R. (2015) Structural and functional properties of the hepatitis C virus p7 viroporin. *Viruses*, **7**, 4461-4481.
- [15] Scheel TK, Rice CM. (2013) Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. *Nature Medicine*, **19**, 837-849.
- [16] Salam KA, Akimitsu N. (2013) Hepatitis C virus NS3 inhibitors: current and future perspectives. *BioMed Research International*, **2013**, 467869.
- [17] Lindenbach BD, Rice CM. (2013) The ins and outs of hepatitis C virus entry and assembly. *Nature Reviews Microbiology*, **11**, 688-700.
- [18] Zeisel MB, Crouch E, Baumert TF, Schuster C. (2015) Host-targeting agents to prevent and cure hepatitis C virus infection. *Viruses*, **7**, 5659-5685.
- [19] Popescu CI, Riva L, Vlaicu O, Farhat R, Rouille Y, Dubuisson J. (2014) Hepatitis C virus life cycle and lipid metabolism. *Biology (Basel)*, **3**, 892-921.
- [20] Trivella JP, Gutierrez J, Martin P. (2015) Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C. *Expert Opinion on Pharmacotherapy*, **16**, 617-624.
- [21] Wahyuni TS, Tumewu L, Permanasari AA, Apriani E, Adianti M, Rahman A, Widyawaruyanti A, Lusida MI, Fuad A, Soetjipto D, Nasronudin D, Fuchino H, Kawahara N, Shoji I, Deng L, Aoki C, Hotta H. (2013) Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus. *Virology Journal*, **10**, 259. (pp. 1-9)
- [22] Wahyuni TS, Widyawaruyanti A, Lusida MI, Fuad A, Soetjipto, Fuchino H, Kawahara N, Hayashi Y, Aoki C, Hotta H. (2014) Inhibition of hepatitis C virus replication by chalepin and pseudane IX isolated from *Ruta angustifolia* leaves. *Fitoterapia*, **99**, 276-283.
- [23] Galani BRT, Sahuc ME, Njayou FN, Deloison G, Mkounga P, Feudjou WF, Brodin P, Rouille Y, Nkengfack AE, Moundipa PF, Seron K. (2015) Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection *in vitro*. *Frontiers in Microbiology*, **6**, 488. (pp. 1-9)
- [24] Adianti M, Aoki C, Komoto M, Deng L, Shoji I, Wahyuni TS, Lusida MI, Soetjipto, Fuchino H, Kawahara N, Hotta H. (2014) Anti-hepatitis C virus compounds obtained from *Glycyrrhiza uralensis* and other *Glycyrrhiza* species. *Microbiology and Immunology*, **58**, 180-187.
- [25] Kong LB, Li SS, Liao QJ, Zhang YN, Sun RN, Zhu XD, Zhang QH, Wang J, Wu XY, Fang XN, Zhu Y. (2013) Oleanolic acid and ursolic acid: Novel hepatitis C virus antivirals that inhibit NS5B activity. *Antiviral Research*, **98**, 44-53.
- [26] Kim JW, Park SJ, Lim JH, Yang JW, Shin JC, Lee SW, Suh JW, Hwang SB. (2013) Triterpenoid saponins isolated from *Platycodon grandiflorum* inhibit hepatitis C virus replication. *Evidence-based Complementary and Alternative Medicine*, **2013**, 560417.
- [27] Lin LT, Chung CY, Hsu WC, Chang SP, Hung TC, Shields J, Russell RS, Lin CC, Li CF, Yen MH, Tyrrell DLJ, Lin CC, Richardson CD. (2015) Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. *Journal of Hepatology*, **62**, 541-548.
- [28] Ravikumar YS, Ray U, Nandhitha M, Perween A, Raja Naika H, Khanna N, Das S. (2011) Inhibition of hepatitis C virus replication by herbal extract: *Phyllanthus amarus* as potent natural source. *Virus Research*, **158**, 89-97.
- [29] Choi M, Kim YM, Lee S, Chin YW, Lee C. (2014) Mangosteen xanthones suppress hepatitis C virus genome replication. *Virus Genes*, **49**, 208-222.
- [30] Wang C, Zhang L, Cheng P, Zhang Q. (2015) Inhibitory effects of *Pinus massoniana* bark extract on hepatitis C virus *in vitro*. *Pharmaceutical Biology*, **53**, 451-456.
- [31] Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno K. (2000) Inhibitory effects of Sudanese medicinal plant extracts on hepatitis C virus (HCV) protease. *Phytotherapy Research*, **14**, 510-516.
- [32] Hsu WC, Chang SP, Lin LC, Li CL, Richardson CD, Lin CC, Lin LT. (2015) *Limonium sinense* and gallic acid suppress hepatitis C virus infection by blocking early viral entry. *Antiviral Research*, **118**, 139-147.
- [33] Ratnoglik SL, Aoki C, Sudarmono P, Komoto M, Deng L, Shoji I, Fuchino H, Kawahara N, Hotta H. (2014) Antiviral activity of extracts from *Morinda citrifolia* leaves and chlorophyll catabolites, pheophorbide a and pyropheophorbide a, against hepatitis C virus. *Microbiology and Immunology*, **58**, 188-194.
- [34] Apriyanto DR, Aoki C, Hartati S, Hanafi M, Kardono LBS, Arsianti A, Louisa M, Sudiro TM, Dewi BE, Sudarmono P, Soebandrio A, Hotta H. (2015) Anti-hepatitis C virus activity of a crude extract from longan (*Dimocarpus longan* Lour.) leaves. *Japanese Journal of Infectious Diseases, advpub*.
- [35] Matsumoto Y, Matsuura T, Aoyagi H, Matsuda M, Hmwe SS, Date T, Watanabe N, Watashi K, Suzuki R, Ichinose S, Wake K, Suzuki T, Miyamura T, Wakita T, Aizaki H. (2013) Antiviral activity of glycyrrhizin against hepatitis C virus *in vitro*. *PLoS One*, **8**, e68992.
- [36] Wang L, Yang R, Yuan B, Liu Y, Liu C. (2015) The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. *Acta Pharmaceutica Sinica B*, **5**, 310-315.
- [37] Jardim AC, Igloi Z, Shimizu JF, Santos VA, Felipe LG, Mazzeu BF, Amako Y, Furlan M, Harris M, Rahal P. (2015) Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication *in vitro*. *Antiviral Research*, **115**, 39-47.
- [38] Batista MN, Carneiro BM, Braga AC, Rahal P. (2015) Caffeine inhibits hepatitis C virus replication *in vitro*. *Archives of Virology*, **160**, 399-407.
- [39] Cao MM, Zhang Y, Li XH, Peng ZG, Jiang JD, Gu YC, Di YT, Li XN, Chen DZ, Xia CF, He HP, Li SL, Hao XJ. (2014) Cyclohexane-fused octahydroquinolizidine alkaloids from *Myriophyllum faberi* with activity against hepatitis C virus. *Journal of Organic Chemistry*, **79**, 7945-7950.
- [40] Lee JC, Tseng CK, Young KC, Sun HY, Wang SW, Chen WC, Lin CK, Wu YH. (2014) Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells. *British Journal of Pharmacology*, **171**, 237-252.
- [41] Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, Steinmann J, Manns MP, Ott M, Wedemeyer H, Meuleman P, Pietschmann T, Steinmann E. (2011) The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. *Hepatology*, **54**, 1947-1955.
- [42] Bhat R, Adam AT, Lee JJ, Deloison G, Rouille Y, Séron K, Rotella DP. (2014) Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors. *Bioorganic & Medicinal Chemistry Letters*, **24**, 4162-4165.
- [43] Wang Y, Li J, Wang X, Pena JC, Li K, Zhang T, Ho W. (2016) (-)-Epigallocatechin-3-gallate enhances hepatitis C virus double-stranded RNA intermediates-triggered innate immune responses in hepatocytes. *Scientific Reports*, **6**, 21595.



- [44] O'Shea D, Law J, Egli A, Douglas D, Lund G, Forester S, Lambert J, Law M, Burton DR, Tyrrell DLJ, Houghton M, Humar A, Kneteman N. (2016) Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. *Liver Transplantation*, **22**, 324-332.
- [45] Calland N, Sahuc ME, Belouzard S, Pene V, Bonnafous P, Mesalam AA, Deloison G, Descamps V, Sahpaz S, Wychowski C, Lambert O, Brodin P, Duverlie G, Meuleman P, Rosenberg AR, Dubuisson J, Rouille Y, Seron K. (2015) Polyphenols inhibit hepatitis C virus entry by a new mechanism of action. *Journal of Virology*, **89**, 10053-10063.
- [46] Elsebai MF, Koutsoudakis G, Saludes V, Perez-Vilaro G, Turpeinen A, Mattila S, Pirttila AM, Fontaine-Vive F, Mehiri M, Meyerhans A, Diez J. (2015) Pan-genotypic hepatitis C virus inhibition by natural products derived from the wild Egyptian artichoke. *Journal of Virology*, **90**, 1918-1930.
- [47] Khachatoorian R, Arumugaswami V, Raychaudhuri S, Yeh GK, Maloney EM, Wang J, Dasgupta A, French SW. (2012) Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle. *Virology*, **433**, 346-355.
- [48] Polyak SJ, Ferenci P, Pawlotsky JM. (2013) Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. *Hepatology*, **57**, 1262-1271.
- [49] Polyak SJ, Oberlies NH, Pecheur EI, Dahari H, Ferenci P, Pawlotsky JM. (2013) Silymarin for HCV infection. *Antiviral Therapy*, **18**, 141-147.
- [50] Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. (2014) Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. *BioMed Research International*, **2014**, 941085.
- [51] Khan H, Paeshuyse J, Murad S, Neyts J. (2016) Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries. *Antiviral Research*, **125**, 43-45.
- [52] Marino Z, Crespo G, D'Amato M, Brambilla N, Giacobelli G, Rovati L, Costa J, Navasa M, Forns X. (2013) Intravenous silybinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. *Journal of Hepatology*, **58**, 415-420.
- [53] Calland N, Dubuisson J, Rouille Y, Seron K. (2012) Hepatitis C virus and natural compounds: a new antiviral approach? *Viruses*, **4**, 2197-2217.
- [54] Shibata C, Ohno M, Otsuka M, Kishikawa T, Goto K, Muroyama R, Kato N, Yoshikawa T, Takata A, Koike K. (2014) The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. *Virology*, **462-463**, 42-48.
- [55] Lovelace ES, Polyak SJ. (2015) Natural products as tools for defining how cellular metabolism influences cellular immune and inflammatory function during chronic infection. *Viruses*, **7**, 6218-6232.
- [56] Ghosh S, Banerjee S, Sil PC. (2015) The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. *Food and Chemical Toxicology*, **83**, 111-124.
- [57] Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frenzen A, Pfaender S, Behrendt P, Brown RJP, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E. (2014) Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. *Gut*, **63**, 1137-1149.
- [58] Prasad S, Tyagi AK, Aggarwal BB. (2014) Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. *Cancer Research and Treatment*, **46**, 2-18.
- [59] Zhong D, Liu M, Cao Y, Zhu Y, Bian S, Zhou J, Wu F, Ryu KC, Zhou L, Ye D. (2015) Discovery of metal ions chelator quercetin derivatives with potent anti-HCV activities. *Molecules*, **20**, 6978-6999.
- [60] Wang H, Wang S, Cheng L, Chen L, Wang Y, Qing J, Huang S, Wang Y, Lei X, Wu Y, Ma Z, Zhang L, Tang Y. (2015) Discovery of imidazo[1,2- $\alpha$ ][1,8]naphthyridine derivatives as potential HCV entry inhibitor. *ACS Medicinal Chemistry Letters*, **6**, 977-981.
- [61] Wang NY, Xu Y, Zuo WQ, Xiao KJ, Liu L, Zeng XX, You XY, Zhang LD, Gao C, Liu ZH, Ye TH, Xia Y, Xiong Y, Song XJ, Lei Q, Peng CT, Tang H, Yang SY, Wei YQ, Yu LT. (2015) Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents. *Journal of Medicinal Chemistry*, **58**, 2764-2778.
- [62] Nair AG, Zeng Q, Selyutin O, Rosenblum SB, Jiang Y, Yang DY, Keertikar K, Zhou G, Dwyer MP, Kim SH, Shankar B, Yu W, Tong L, Chen L, Mazzola R, Caldwell J, Tang H, Allard ML, Buckle RN, Gauvan PJ, Holst CL, Martin GS, Naicker KP, Vellekoop S, Agrawal S, Liu R, Kong R, Ingravallo P, Xia E, Zhai Y, Nomeir A, Kozlowski JA. (2016) Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development. *Bioorganic and Medicinal Chemistry Letters*, **26**, 1475-1479.
- [63] Neelamkavil SF, Agrawal S, Bara T, Bennett C, Bhat S, Biswas D, Brockmeyer L, Buist N, Burnette D, Cartwright M, Chackalamannil S, Chase R, Chelliah M, Chen A, Clasby M, Colandrea VJ, Davies IW, Eagen K, Guo ZY, Han YX, Howe J, Jayne C, Josien H, Kargman S, Marcantonio K, Miao SW, Miller R, Nolting A, Pinto P, Rajagopalan M, Ruck RT, Shah U, Soriano A, Sperbeck D, Velazquez F, Wu J, Xia Y, Venkatraman S. (2016) Discovery of MK-8831, a novel spiro-proline macrocycle as a pan-genotypic HCV-NS3/4a protease inhibitor. *ACS Medicinal Chemistry Letters*, **7**, 111-116.
- [64] Patil VM, Masand N, Gupta SP. (2016) HCV inhibitors: role of compounds from botanical sources. *Current Topics in Medicinal Chemistry*, **16**, 1402-1409.
- [65] Li Y, Yu S, Liu D, Proksch P, Lin W. (2012) Inhibitory effects of polyphenols toward HCV from the mangrove plant *Excoecaria agallocha* L. *Bioorganic & Medicinal Chemistry Letters*, **22**, 1099-1102.
- [66] Qian XJ, Zhu YZ, Zhao P, Qi ZT. (2016) Entry inhibitors: New advances in HCV treatment. *Emerging Microbes and Infections*, **5**, e3.
- [67] Fernandes TA, Manvar D, Domingos JL, Basu A, Nichols DB, Kaushik-Basu N, Costa PR. (2016) 5-Carba-pterocarpenes: a new scaffold with anti-HCV activity. *European Journal of Medicinal Chemistry*, **112**, 33-38.
- [68] Zhang N, Turpoff A, Zhang X, Huang S, Liu Y, Almstead N, Njoroge FG, Gu Z, Graci J, Jung SP, Pichardo J, Colacino J, Lahser F, Ingravallo P, Weetall M, Nomeir A, Karp GM. (2016) Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B. *Bioorganic & Medicinal Chemistry Letters*, **26**, 594-601.
- [69] Perin PM, Haid S, Brown RJP, Doerrbecker J, Schulze K, Zeilinger C, von Schawen M, Heller B, Vercauteren K, Luxenburger E, Baktash YM, Vondran FWR, Speerstra S, Awadh A, Mukhtarov F, Schang LM, Kirschning A, Müller R, Guzman CA, Kaderali L, Randall G, Meuleman P, Ploss A, Pietschmann T. (2016) Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. *Hepatology*, **63**, 49-62.
- [70] Prigozhin DM, Modis Y. (2016) Flunarizine arrests hepatitis C virus membrane fusion. *Hepatology*, **63**, 14-16.
- [71] Colpitts CC, Baumert TF. (2016) Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals. *Hepatology International*, (Epub ahead of print).
- [72] Mizui T, Yamashina S, Tanida I, Takei Y, Ueno T, Sakamoto N, Ikejima K, Kitamura T, Enomoto N, Sakai T, Kominami E, Watanabe S. (2010) Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. *Journal of Gastroenterology*, **45**, 195-203.
- [73] Vausselet T, Calland N, Belouzard S, Descamps V, Douam F, Helle F, Francois C, Lavillette D, Duverlie G, Wahid A, Feneant L, Cocquerel L, Guerardel Y, Wychowski C, Biot C, Dubuisson J. (2013) The antimalarial ferroquine is an inhibitor of hepatitis C virus. *Hepatology*, **58**, 86-97.
- [74] Cannalire R, Barreca ML, Manfroni G, Cecchetti V. (2016) A journey around the medicinal chemistry of hepatitis C virus inhibitors targeting NS4B: from target to preclinical drug candidates. *Journal of Medicinal Chemistry*, **59**, 16-41.



<b>Structure of a Coumaric Acid Analogue with a Monoterpene Moiety from the Flowers of <i>Osmanthus fragrans</i> var. <i>aurantiacus</i> and Evaluation of Cinnamic Acid Analogues as Nitric Oxide Production and Degranulation Inhibitors</b> Seikou Nakamura, Jiang Liu, Souichi Nakashima, Keiko Ogawa, Takashi Ueda, Eri Onishi, Kiwako Kurooka, Yuko Moriwaki, Kaori Ryu, Bin Xu, Takahiro Matsumoto, Tomoe Ohta, Masashi Fukaya, Masayuki Yoshikawa and Hisashi Matsuda	1123
<b>Identification of Cardioactive <i>Leonurus</i> and <i>Leonotis</i> Drugs by Quantitative HPLC Determination and HPTLC Detection of Phenolic Marker Constituents</b> Kenny Kuchta, Jutta Ortwein, İhsan Çaliş, Rainer B. Volk and Hans W. Rauwald	1129
<b>Macrocyclization Using RCM Reactions. Synthesis of Simple Metacyclophanes and Synthetic Efforts Toward Platycaryanol, a 15-Membered Aromatic Ether</b> Katsuyuki Nakashima, Hatsuna Matsunaga, Masako Ito, Hiroshi Minami, Akihiro Aiba, Norihiro Fujisaki and Motoo Tori	1135
<b>Secondary Metabolites from Fungal Endophytes of <i>Echinacea purpurea</i> Suppress Cytokine Secretion by Macrophage-Type Cells</b> Amninder Kaur, Martina Oberhofer, Monika Juzumaite, Huzefa A. Raja, Travis V. Gullledge, Diana Kao, Stanley H. Faeth, Scott M. Laster, Nicholas H. Oberlies and Nadja B. Cech	1143
<b>Two Novel Diphenolic Metabolites from the Inedible Mushroom <i>Thelephora palmata</i></b> Ayako Nishio, Haruka Mikami, Hiroshi Imagawa, Toshihiro Hashimoto, Masami Tanaka, Takuya Ito, Miki Iguchi, Kanako Iseki, Masaaki Noji and Akemi Umeyama	1147
<b>Virgin Coconut Oil and its Cardiovascular Health Benefits</b> Zheng Fei Ma and Yeong Yeh Lee	1151
<b>Influence of Thermal Processing and <i>in vitro</i> Digestion on the Antioxidant Potential of Ginger and Ginger Containing Products</b> Wojciech Koch, Wirginia Kukula-Koch, Marcin Dziedzic, Kazimierz Głowniak and Yoshinori Asakawa	1153
<b>Analysis of Carotenoids, Flavonoids and Essential Oil of <i>Calendula officinalis</i> Cultivars Growing in Estonia</b> Ain Raal, Anne Orav, Julia Nesterovitsch and Kerttu Maidla	1157
<b>Volatile Constituents of New Caledonian <i>Frullania</i> Species</b> Benjamin Métoyer, Paul Couleric, Nicolas Leboviev, Edouard Hnawia, Louis Thouvenot, Yoshinori Asakawa, Phila Raharivelomanana and Mohammed Nour	1161
<b>Characteristic Volatile Components of Trifoliolate Orange Peel (<i>Poncirus trifoliata</i>)</b> Kenichi Tomiyama, Kazutoshi Sakurai, Yoshihiro Yaguchi, Yukihiro Kawakami and Yoshinori Asakawa	1165
<b>Composition and Chemical Variability of the Cone Oil from Algerian <i>Tetraclinis articulata</i></b> Maghnia Boussaïd, Chahrazed Bekhechi, Fewzia Atik-Bekkara, Mathieu Paoli, Joseph Casanova and Félix Tomi	1167
<b>Characteristic Aroma Features of Tencha and Sencha Green Tea Leaves Manufactured by Different Processes</b> Toshio Hasegawa, Yuta Shimada, Hiroki Saito, Takashi Fujihara, Kenji Haraguchi, Atsushi Takahashi and Kenta Nakajima	1171
<b>Enhancement of Pentobarbital-induced Sleep by the Vaporized Essential Oil of <i>Citrus keraji</i> var. <i>kabuchii</i> and its Characteristic Component, <math>\gamma</math>-Terpinene</b> Yoshinori Kobayashi, Hiroaki Takemoto, Ziqi Fu, Emiko Shimizu and Yukitaka Kinjo	1175
<b>Odor-Active Components of Luo Han Guo (<i>Siraitia grosvenorii</i>)</b> Kenichi Tomiyama, Kazutoshi Sakurai, Yoshihiro Yaguchi and Yukihiro Kawakami	1179
<b><u>Accounts/Reviews</u></b>	
<b>Research Progress on Natural Benzophenanthridine Alkaloids and their Pharmacological Functions: A Review</b> Na Han, Zhiyou Yang, Zhihui Liu, Huijing Liu and Jun Yin	1181
<b>Dinitrosyl Iron Complexes and other Physiological Metabolites of Nitric Oxide: Multifarious Role in Plants</b> Konstantin B. Shumaev, Olga V. Kosmachevskaya, Ludmila V. Chumikina and Alexey F. Topunov	1189
<b>Promising Anti-Hepatitis C Virus Compounds from Natural Resources</b> Tutik Sri Wahyuni, Chie Aoki Utsubo and Hak Hotta	1193
<b>Neural Transmission from Oropharyngeal Bitter Receptors to the Medulla is Partially or Completely Labelled-Line</b> Michael K McMullen	1201



# Natural Product Communications

## 2016

Volume 11, Number 8

### Contents

#### Editorial

Gerald Blunden and Pawan K. Agrawal

i

#### Preface

Simon Gibbons

iii

#### Family Message

Hisa Asakawa, Yoko and Tomomi Asakawa

iv

#### Original Paper

- Chemical and Genetic Study of two *Ligularia* Hybrids in Shangrila County, Yunnan Province, China**  
Ryo Hanai, Sayako Tanabe, Nao Aoyama, Yasuko Okamoto, Motoo Tori, Ningning Zhang, Xun Gong and Chiaki Kuroda 1057
- A Puna Collection of *Senecio punae*, Main Source of a Versatile Eremophilane-type Ketone**  
Ana María Rodríguez, Susana Montanaro, Alicia Bardón, Elena Cartagena and Susana Borkosky 1061
- Cappermacrene C, a New Sesquiterpenoid from a Bornean Soft Coral, *Capnella* sp.**  
Takahiro Ishii, Chin-Soon Phan, Takashi Kamada and Charles Santharaju Vairappan 1065
- Cyclization into Hydrindanes Using Samarium Diodide: Stereochemical Features Depending on the Protecting Group**  
Masakazu Sono, Yukiko Nishibuchi, Norihito Yamaguchi and Motoo Tori 1067
- A New *Seco*-Clerodane-Type Diterpenoid from Bornean Liverwort *Schistochila acuminata***  
Shean-Yeaw Ng, Takashi Kamada, Monica Suleiman and Charles S. Vairappan 1071
- Daphnane Diterpenoids from *Daphne altaica***  
Alfarius Eko Nugroho, Wong Chin-Piow, Yusuke Hirasawa, Jenis Janar, Toshio Kaneda, Osamu Shiota and Hiroshi Morita 1073
- 16-Hydroxycembra-1,3,7,11-tetraene, a new Cembrane Diterpene from Malaysian Soft Coral Genus *Sarcophyton***  
Takashi Kamada, Chin-Soon Phan, Hoe-Seng Tin, Charles Santharaju Vairappan and Tengku Sifzizul Tengku Muhammad 1077
- A Novel 3,4-Secocycloartane Triterpene, Bearing a Tetrahydropyran Moiety, from *Pasania formosana* Leaf**  
Shoei-Sheng Lee, Yue Xi, Chien-Kuang Chen, Ching-Chia Chang and Sheng-Fa Tsai 1079
- Three Tetracyclic Triterpenoic Acids from *Dysoxylum densiflorum* and Their Antibacterial Activities**  
Ni Komang T. Dharmayani, Lia D. Juliawaty and Yana M. Syah 1081
- Six New Triterpenoids from the Aerial Parts of *Maytenus diversifolia***  
Narumi Anoda, Mayumi Matsunaga, Miwa Kubo, Kenichi Harada and Yoshiyasu Fukuyama 1085
- Optimization of 3', 4'-Anhydrovinblastine Synthesis *in vitro* Using Crude Extracts of *Catharanthus roseus* Irradiated with Near-Ultraviolet Light**  
Mamiko Asano, Kazuo Harada, Akiko Umeno and Kazumasa Hirata 1089
- De novo* Biosynthesis of Trigonelline in Fenugreek (*Trigonella foenum-graecum*) seedlings**  
Hiroshi Ashihara 1093
- Glycosylation of Chrysin by Cultured Cells of *Eucalyptus perriniana***  
Kei Shimoda, Naoji Kubota, Masato Tanigawa and Hiroki Hamada 1097
- Estrogenic and Anti-estrogenic Constituents of *Erythrina caffra***  
Yu-Ming Hsu, Wan-Chun Lai, Chi-Ying Li, Yu-Hsuan Lan, Yu-Chi Tsai, Attila Hunyadi, Ming-Feng Hou, Shyng-Shiou Yuan, Yang-Chang Wu and Fang-Rong Chang 1099
- A New Bioactive Secondary Metabolite from *Artocarpus elasticus***  
Faiqah Ramli, Mawardi Rahmani, Intan Safinar Ismail, Mohd Aspollah Sukari, Mashitoh Abd Rahman, Asdren Zajmi, Abdah Md Akim, Najihah Mohd Hashim and Rusea Go 1103
- Development of an Efficient Protocol for Cimifugin Isolation from *Peucedanum schottii* and Evaluation of Enzyme Inhibitory Activity**  
Ewelina Koziol, Ilkay Erdogan Orhan, F. Sezer Senol, Kalina Alipieva, Milen Georgiev and Krystyna Skalicka-Wozniak 1107
- Pyranonigrin L, a New Antioxidant, Produced by the Hot Spring-derived Fungus *Penicillium adametzii* BF-0003**  
Ryuji Uchida, Hidetoshi Miyazaki, Yuichi Yamaguchi, Hiroyuki Ishijima and Hiroshi Tomoda 1111
- Lignans from the Whole Plants of *Hedyotis uncinella***  
Yaping Pan, Yan Zhang, Chao Fan, Yu Zhang, Shikai Yan, Huizi Jin and Weidong Zhang 1115
- Biological Activities of Isolated Compounds from Three Edible Malaysian Red Seaweeds, *Gracilaria changii*, *G. manilaensis* and *Gracilaria* sp.**  
Yosie Andriani, Desy Fitriya Syamsumir, Tee Ching Yee, Faizah Shaharom Harisson, Gan Ming Herng, Siti Aishah Abdullah @ Christine Abellana Oroasco, Abdul Manaf Ali, Jalifah Latip, Hiroe Kikuzaki and Habsah Mohamad 1117
- Optical Resolution of (*RS*)-Denopamine to (*R*)-Denopamine  $\beta$ -D-Glucoside by Glucosyltransferase from *Phytolacca americana* Expressed in Recombinant *Escherichia coli***  
Hiroki Hamada, Shouta Okada, Kei Shimoda, Daisuke Uesugi and Hatsuyuki Hamada 1121

Continued inside backcover